The healthcare solutions in which the foreign delegation has shown interest include labour-saving technologies, remote ...

Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system (CNS) disorders, announces today a ...

Enrollment completed in Phase 2a CBeyond trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Niagen Bioscience fair value estimate is US$7.16 With ...

NEW YORK--(BUSINESS WIRE)--Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia which ...